https://gloxtherapeutics.com/wp-content/uploads/2023/11/news.png 677 1000 duncanweddell@gmail.com https://gloxtherapeutics.com/wp-content/uploads/2023/10/Glox-Therapeutics.png duncanweddell@gmail.com2025-02-11 11:15:542025-02-11 11:16:16Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member https://gloxtherapeutics.com/wp-content/uploads/2023/11/news.png 677 1000 duncanweddell@gmail.com https://gloxtherapeutics.com/wp-content/uploads/2023/10/Glox-Therapeutics.png duncanweddell@gmail.com2025-01-21 12:52:152025-01-21 12:52:15Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
https://gloxtherapeutics.com/wp-content/uploads/2024/11/glox-pace2-2.png 677 1000 duncanweddell@gmail.com https://gloxtherapeutics.com/wp-content/uploads/2023/10/Glox-Therapeutics.png duncanweddell@gmail.com2024-11-20 10:05:352024-11-20 10:09:30Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens
https://gloxtherapeutics.com/wp-content/uploads/2024/11/gloxgu.png 534 1000 duncanweddell@gmail.com https://gloxtherapeutics.com/wp-content/uploads/2023/10/Glox-Therapeutics.png duncanweddell@gmail.com2024-11-19 15:10:042024-11-19 15:10:04Glox Therapeutics has been shortlisted for the @University of Glasgow Spin-out of the Year award https://gloxtherapeutics.com/wp-content/uploads/2023/11/news.png 677 1000 James Clark https://gloxtherapeutics.com/wp-content/uploads/2023/10/Glox-Therapeutics.png James Clark2023-11-14 08:56:502023-11-14 08:56:50Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria